Companies › Sichuan Baili Pharmaceutical
21 active drug programs in 135 registered trials: 57 Phase 1, 53 Phase 2, 25 Phase 3; Oncology, Gastroenterology, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BL-B01D1 Anti-TROP2 antibody-drug conjugate | TROP-2, TROP2, TACSTD2 | Phase 3 | Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer; Epithelial Ovarian Cancer … | Nov 2026 |
| SI-B001 EGFR/HER3 bispecific antibody | EGFR, HER3 | Phase 3 | Non-small Cell Lung Adenocarcinoma; Non-small Cell Lung Cancer; Esophageal Squamous Cell Carcinomas; Head and Neck Squamous Cell Carcinoma … | Nov 2026 |
| BL-M07D1 anti-HER2 antibody-drug conjugate | ERBB2 | Phase 3 | HER2-low Breast Cancer; Gastric Adenocarcinoma; Non-squamous Non-small Cell Lung Cancer; HER2-positive Breast Cancer … | Dec 2026 |
| Tislelizumab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Extensive-stage Small-cell Lung Cancer; Urothelial Carcinoma; Esophageal Squamous Cell Carcinoma | Dec 2026 |
| SI-B003 PD-1/CTLA-4 bispecific antibody | PDCD1, CTLA4 | Phase 2 | Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma; Small Cell Lung Cancer; Cervical Cancer … | Nov 2026 |
| BL-M11D1 | – | Phase 2 | Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Dec 2026 |
| PD-1 Monoclonal Antibody PD-1 inhibitor | PDCD1 | Phase 2 | HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma; Triple-negative Breast Cancer; Extensive-stage Small-cell Lung Cancer; Esophageal Cancer … | Dec 2026 |
| Pertuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 2 | HER2-positive Breast Cancer | Dec 2028 |
| BL-M08D1 | – | Phase 1 | Solid Tumor; Relapsed or Refractory Lymphoid Malignancies; Melanoma; Gastrointestinal Tumors | Dec 2026 |
| GNC-035 Tetra-specific antibody | – | Phase 1 | Breast Cancer; Hematologic Malignancies; Relapsed/Refractory Chronic Lymphocytic Leukemia; Non-hodgkin's Lymphoma | Dec 2026 |
| GNC-038 Tetra-specific antibody | – | Phase 1 | Primary Central Nervous System Lymphoma; Non Hodgkin Lymphoma; NK/T Cell Lymphoma; Diffuse Large B-cell Lymphoma … | Dec 2026 |
| GNC-039 Tetra-specific antibody | – | Phase 1 | Recurrent Glioma | Dec 2026 |
| BL-M09D1 | – | Phase 1 | Gastrointestinal Tumor; Non-small Cell Lung Cancer | May 2027 |
| BL-M24D1 | – | Phase 1 | Head and Neck Squamous Cell Carcinoma; Gastrointestinal Tumors; Multiple Myeloma; Non Small Cell Lung Cancer | Nov 2027 |
| BL-ARC002 | – | Phase 1 | Solid Tumors; Gastrointestinal Tumors | Dec 2027 |
| Lutetium [177Lu]-BL-ARC001 Radioligand therapy targeting somatostatin receptor 2 (SSTR2) | – | Phase 1 | Lung Cancer; Gastrointestinal Tumors | Dec 2027 |
| SI-B036 bispecific antibody | – | Phase 1 | Solid Tumor; Breast Cancer; Head and Neck Tumors; Gastrointestinal Tumor | Dec 2028 |
| BL-B16D1 | – | Phase 1 | Head and Neck Squamous Cell Carcinomas; Breast Cancer; Solid Tumor | – |
| BL-M02D1 | – | Phase 1 | Locally Advanced or Metastatic Digestive Tract Tumors; Non-small Cell Lung Cancer; Breast Cancer | – |
| BL-M17D1 HER2-targeting therapy (specific mechanism unclear from registry) | – | Phase 1 | Esophageal Cancer; Breast Cancer | – |
| GNC-077 | – | Phase 1 | Breast Cancer; Non-small Cell Lung Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05393427 | BL-B01D1 | Phase 1 | Locally Advanced or Metastatic Urinary Tumors | Oncology | Dec 2025 |
| NCT05020769 | SI-B001 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT05022654 | SI-B001 | Phase 2 | Esophageal Squamous Cell Carcinomas | Oncology | Dec 2025 |
| NCT05044897 | SI-B001 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2025 |
| NCT05020457 | SI-B001 | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT04603287 | SI-B001 | Phase 1 | Locally Advanced or Metastatic Epithelial Tumor | Oncology | Dec 2025 |
| NCT04606472 | SI-B003 | Phase 1 | Solid Tumor | Oncology | Dec 2025 |
| NCT05485753 | GNC-038 | Phase 1 | Primary Central Nervous System Lymphoma | Oncology | Dec 2025 |
| NCT04606433 | GNC-038 | Phase 1 | Non Hodgkin Lymphoma | Oncology | Dec 2025 |
| NCT05627856 | GNC-038 | Phase 1 | NK/T Cell Lymphoma | Oncology | Dec 2025 |
| NCT05192486 | GNC-038 | Phase 1 | Diffuse Large B-cell Lymphoma | Oncology | Dec 2025 |
| NCT05160545 | GNC-035 | Phase 1 | Breast Cancer | Oncology | Dec 2025 |
| NCT05104775 | GNC-035 | Phase 1 | Hematologic Malignancies | Oncology | Dec 2025 |
| NCT05944978 | GNC-035 | Phase 1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | Oncology | Dec 2025 |
| NCT05385692 | BL-M02D1 | Phase 1 | Locally Advanced or Metastatic Digestive Tract Tumors | Oncology | Dec 2025 |
| NCT05949619 | BL-M02D1 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT05339685 | BL-M02D1 | Phase 1 | Breast Cancer | Oncology | Dec 2025 |
| NCT05943795 | SI-B001 | Phase 3 | Non-small Cell Lung Adenocarcinoma | Oncology | Jul 2026 |
| NCT06469008 | BL-B16D1 | Phase 1 | Head and Neck Squamous Cell Carcinomas | Oncology | Jul 2026 |
| NCT06493864 | BL-B16D1 | Phase 1 | Breast Cancer | Oncology | Jul 2026 |
| NCT06475131 | BL-B16D1 | Phase 1 | Solid Tumor | Oncology | Jul 2026 |
| NCT06500052 | BL-M17D1 | Phase 1 | Esophageal Cancer | Oncology | Aug 2026 |
| NCT06503783 | BL-M17D1 | Phase 1 | Breast Cancer | Oncology | Aug 2026 |
| NCT06598787 | BL-B01D1 | Phase 2 | Recurrent Glioblastoma | Oncology | Oct 2026 |
| NCT06423885 | PD-1 Monoclonal Antibody | Phase 2 | HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Oct 2026 |
| NCT06423885 | BL-M07D1 | Phase 2 | HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Oct 2026 |
| NCT06609187 | GNC-077 | Phase 1 | Breast Cancer | Oncology | Oct 2026 |
| NCT06612840 | GNC-077 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Oct 2026 |
| NCT06118333 | BL-B01D1 | Phase 3 | Nasopharyngeal Carcinoma | Oncology | Nov 2026 |
| NCT06668961 | SI-B001 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Nov 2026 |
| NCT06668961 | SI-B003 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Nov 2026 |
| NCT06500026 | BL-B01D1 | Phase 3 | Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06382129 | BL-B01D1 | Phase 3 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06471205 | BL-B01D1 | Phase 2 | Triple-negative Breast Cancer | Oncology | Dec 2026 |
| NCT05965856 | BL-B01D1 | Phase 2 | Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT05924841 | BL-B01D1 | Phase 2 | Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05990803 | BL-B01D1 | Phase 2 | Cervical Cancer | Oncology | Dec 2026 |
| NCT06437509 | BL-B01D1 | Phase 2 | Extensive-stage Small-cell Lung Cancer | Oncology | Dec 2026 |
| NCT05956587 | BL-B01D1 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06405425 | BL-B01D1 | Phase 2 | Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT05785039 | BL-B01D1 | Phase 2 | Urinary System Tumor | Oncology | Dec 2026 |
| NCT06008054 | BL-B01D1 | Phase 2 | Esophageal Cancer | Oncology | Dec 2026 |
| NCT06006169 | BL-B01D1 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT06042894 | BL-B01D1 | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT05194982 | BL-B01D1 | Phase 1 | Locally Advanced or Metastatic Solid Tumor | Oncology | Dec 2026 |
| NCT05803018 | BL-B01D1 | Phase 1 | Gynecological Malignant Tumor | Oncology | Dec 2026 |
| NCT05262491 | BL-B01D1 | Phase 1 | Gastrointestinal Tumor | Gastroenterology | Dec 2026 |
| NCT05470348 | BL-B01D1 | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT06471205 | PD-1 Monoclonal Antibody | Phase 2 | Triple-negative Breast Cancer | Oncology | Dec 2026 |
| NCT06437509 | PD-1 Monoclonal Antibody | Phase 2 | Extensive-stage Small-cell Lung Cancer | Oncology | Dec 2026 |
| NCT06008054 | PD-1 Monoclonal Antibody | Phase 2 | Esophageal Cancer | Oncology | Dec 2026 |
| NCT05054439 | SI-B001 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT05668858 | SI-B001 | Phase 1 | Squamous Cell Carcinoma of Head and Neck | Oncology | Dec 2026 |
| NCT05949606 | SI-B001 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05965856 | SI-B003 | Phase 2 | Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT05924841 | SI-B003 | Phase 2 | Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05990803 | SI-B003 | Phase 2 | Cervical Cancer | Oncology | Dec 2026 |
| NCT05956587 | SI-B003 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06008054 | SI-B003 | Phase 2 | Esophageal Cancer | Oncology | Dec 2026 |
| NCT06006169 | SI-B003 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2026 |
The 60 nearest readouts of 135 trials; the rest in the app.
Shanghai Henlius Biotech Sichuan Kelun-Biotech Biopharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shenyang Sunshine Pharmaceutical Akeso
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.